Tiblio
Sign Up

NEUP

Neuphoria Therapeutics Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$19.40M
P/E Ratio
—
EPS
$-7.90
Beta
—
52W High
$21.40
52W Low
$3.19
50-Day MA
$4.76
200-Day MA
$5.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc (Ticker: NEUP) is a groundbreaking biotechnology firm focused on revolutionizing the treatment of mental health disorders through the development of innovative therapies leveraging psychedelic compounds and advanced drug delivery systems. The company boasts a promising pipeline of preclinical candidates aimed at addressing significant unmet needs in mental health care, amidst a landscape increasingly favorable for effective therapeutic alternatives. As a frontrunner in the burgeoning psychedelic therapy sector, Neuphoria offers a compelling opportunity for institutional investors seeking to engage with transformative healthcare trends that have the potential to reshape the mental health treatment paradigm.

Official WebsiteUSAFY End: June

Fundamentals

Revenue (TTM)-13,267
Gross Profit (TTM)-13,267
EBITDA$-14.00M
Operating Margin110513.00%
Return on Equity-62.90%
Return on Assets-28.00%
Revenue/Share (TTM)$-0.00
Book Value$5.47
Price-to-Book0.62
Price-to-Sales (TTM)1.70
EV/Revenue0.224
EV/EBITDA-0.06
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$5.40M
Float$4.19M
% Insiders7.70%
% Institutions55.03%

Historical Volatility

HV 10-Day
117.51%
HV 20-Day
85.64%
HV 30-Day
77.51%
HV 60-Day
65.39%
HV Rank
—

Volatility is currently expanding

Analyst Ratings

Consensus ($7.00 target)
1
Strong Buy
1
Buy

Latest News

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings plc (“Scancell”).

GlobeNewsWire6/26/2026Neutral

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncUNHUnitedHealth Group IncorporatedMRKMerck & Company IncNVSNovartis AG ADRAZNAstraZeneca PLCNVONovo Nordisk A/SAMGNAmgen IncTMOThermo Fisher Scientific IncGILDGilead Sciences IncABTAbbott Laboratories
View all HEALTHCARE stocks →
Data last updated: 7/9/2026